NCT05486312 is a NA clinical trial of CT-155 smartphone app in Schizophrenia, sponsored by Click Therapeutics, Inc..

Who is sponsoring NCT05486312?

NCT05486312 is sponsored by Click Therapeutics, Inc..

What drugs are being tested in NCT05486312?

Interventions in NCT05486312: CT-155 smartphone app.

What condition does NCT05486312 study?

NCT05486312 studies Schizophrenia.

Is NCT05486312 still recruiting?

NCT05486312 is currently completed. Last updated 15 May 2025.

Last reviewed 2025-05-15 · How we verify

NCT05486312

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

7-week Study With CT-155 in People With Schizophrenia

Completed NA Last updated 15 May 2025

What this trial tests

NA trial testing CT-155 smartphone app in Schizophrenia in 72 participants. Completed in 12 December 2022.

Timeline

5 July 2022

Primary endpoint
22 September 2022

12 December 2022

Quick facts

Lead sponsor	Click Therapeutics, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	device feasibility
Enrollment	72
Start date	5 July 2022
Primary completion	22 September 2022
Estimated completion	12 December 2022
Sites	10 locations across United States

Drugs / interventions tested

CT-155 smartphone app

Conditions studied

Schizophrenia — all drugs for Schizophrenia →

Sponsor

Click Therapeutics, Inc.

Who can join

Adults 18 to 64, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CT-155 is a novel prescription digital therapeutic (PDT) to treat schizophrenia

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Establishment and Maintenance of a Digital Therapeutic Alliance in People Living With Negative Symptoms of Schizophrenia: Two Exploratory Single-Arm Studies.
Snipes C, Dorner-Ciossek C, Hare BD, Besedina O, et al · · 2025 · cited 5× · PMID 39869902 · DOI 10.2196/64959
Feasibility of a digital therapeutic for experiential negative symptoms of schizophrenia: results from an exploratory study.
Goenjian H, Pratap A, Snipes C, Hare BD, et al · · 2025 · cited 2× · PMID 41006305 · DOI 10.1038/s41537-025-00659-1
Patient Perspectives on a Digital Therapeutic for Schizophrenia: A Qualitative Evaluation of an App for Negative Symptoms.
Gandhi A, Firmin RL, Luther L, Wahid N, et al · · 2025 · PMID 41333683 · DOI 10.1093/schizbullopen/sgaf028

Verify or expand the search:

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting

Other Click Therapeutics, Inc. trials

Trials by the same sponsor.

NCT06486948 — An Exploratory, Double-arm, 8-week Study to Explore the Feasibility and Acceptability of Abbreviated Treatment with CT-1 · NA · completed
NCT06275659 — An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis · NA · completed
NCT06136923 — An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer · NA · completed
NCT06136936 — A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia · NA · completed
NCT06067984 — An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Sc · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05486312 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Click Therapeutics, Inc.
Last refreshed: 15 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05486312.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing